Henry Schein to Serve as Exclusive Distributor of Curodont to Dental Service Organizations
Henry Schein (Nasdaq: HSIC) has secured an exclusive distribution agreement with Swiss company vVARDIS for their Curodont™ Repair Fluoride Plus product to larger dental service organizations (DSOs) in the U.S. This innovative, drill-free solution addresses early-stage tooth decay, aiding in preventive treatment of cavity progression.
The partnership aims to expand patient care with a non-invasive approach, as nearly 80% of patients show signs of early decay. Henry Schein's CEO, Stanley M. Bergman, emphasized the product's ability to treat early-stage caries non-invasively and on the same day. The agreement complements Henry Schein One's Dentrix® Detect AI, an AI-enabled X-ray analysis tool introduced in late 2022, which can detect incipient carious lesions more accurately than the naked eye.
Henry Schein (Nasdaq: HSIC) ha stipulato un accordo di distribuzione esclusivo con l'azienda svizzera vVARDIS per il loro prodotto Curodont™ Repair Fluoride Plus, destinato a grandi organizzazioni di servizi odontoiatrici (DSO) negli Stati Uniti. Questa soluzione innovativa, che non richiede trapani, affronta le prime fasi della carie dentale, supportando il trattamento preventivo della progressione delle cavità.
La partnership si propone di ampliare le cure per i pazienti con un approccio non invasivo, poiché quasi l'80% dei pazienti presenta segni di carie precoce. Il CEO di Henry Schein, Stanley M. Bergman, ha sottolineato la capacità del prodotto di trattare le carie in fase iniziale in modo non invasivo e nella stessa giornata. L'accordo si integra con Dentrix® Detect AI di Henry Schein One, uno strumento di analisi delle radiografie abilitato all'IA introdotto alla fine del 2022, che può rilevare le lesioni cariose incipienti con maggiore precisione rispetto all'occhio nudo.
Henry Schein (Nasdaq: HSIC) ha conseguido un acuerdo de distribución exclusivo con la empresa suiza vVARDIS para su producto Curodont™ Repair Fluoride Plus, dirigido a grandes organizaciones de servicios dentales (DSO) en los EE. UU. Esta innovadora solución sin taladro aborda la caries dental en etapas tempranas, ayudando en el tratamiento preventivo de la progresión de las cavidades.
La asociación tiene como objetivo expandir la atención al paciente con un enfoque no invasivo, ya que casi el 80% de los pacientes muestra signos de caries temprana. El CEO de Henry Schein, Stanley M. Bergman, enfatizó la capacidad del producto para tratar caries en etapa temprana de manera no invasiva y en el mismo día. El acuerdo complementa Dentrix® Detect AI de Henry Schein One, una herramienta de análisis de rayos X habilitada por IA que se introdujo a finales de 2022 y que puede detectar lesiones cariosas incipientes con mayor precisión que el ojo humano.
헨리 샤인 (Nasdaq: HSIC)은 스위스 회사 vVARDIS와 미국의 대형 치과 서비스 조직(DSO)을 위한 Curodont™ Repair Fluoride Plus 제품의 독점 배급 계약을 체결했습니다. 이 혁신적인 무드릴 솔루션은 초기 단계의 충치를 해결하며, 충치 진행의 예방 치료에 도움을 줍니다.
이 파트너십은 약 80%의 환자들이 초기 충치의 징후를 보이고 있는 만큼 비침습적인 접근 방식을 통해 환자 치료를 확장하는 것을 목표로 합니다. 헨리 샤인의 CEO인 스탠리 M. 버그먼은 제품이 초기 단계의 충치를 비침습적으로 하루 만에 치료할 수 있는 능력을 강조했습니다. 이 계약은 2022년 후반에 도입된 AI 기반 엑스레이 분석 도구인 Dentrix® Detect AI와 상보적이며, 이는 육안보다 초기 충치 병변을 더 정확하게 감지할 수 있습니다.
Henry Schein (Nasdaq: HSIC) a conclu un accord de distribution exclusif avec la société suisse vVARDIS pour son produit Curodont™ Repair Fluoride Plus, destiné aux grandes organisations de services dentaires (DSO) aux États-Unis. Cette solution innovante, sans forage, traite les premiers stades de la carie dentaire, aidant au traitement préventif de la progression des caries.
Le partenariat vise à élargir les soins aux patients avec une approche non invasive, puisque près de 80 % des patients montrent des signes de carie précoce. Le PDG de Henry Schein, Stanley M. Bergman, a souligné la capacité du produit à traiter les caries à un stade précoce de manière non invasive et le même jour. L'accord complète Dentrix® Detect AI de Henry Schein One, un outil d'analyse des rayons X activé par IA introduit fin 2022, qui peut détecter les lésions carieuses incipientes plus précisément que l'œil nu.
Henry Schein (Nasdaq: HSIC) hat eine exklusive Vertriebsvereinbarung mit dem Schweizer Unternehmen vVARDIS für ihr Produkt Curodont™ Repair Fluoride Plus für große Dentaldienstleister (DSO) in den USA gesichert. Diese innovative, bohrfreie Lösung adressiert frühe Zahnverfallstadien und unterstützt die präventive Behandlung der Kariesentwicklung.
Die Partnerschaft zielt darauf ab, die Patientenversorgung mit einem nicht-invasiven Ansatz zu erweitern, da fast 80 % der Patienten Anzeichen von frühem Zahnverfall aufweisen. Der CEO von Henry Schein, Stanley M. Bergman, betonte die Fähigkeit des Produkts, frühzeitige Karies nicht-invasiv und am selben Tag zu behandeln. Die Vereinbarung ergänzt Dentrix® Detect AI von Henry Schein One, ein KI-gestütztes Röntgenanalysetool, das Ende 2022 eingeführt wurde und das beginnende kariösen Läsionen präziser erkennen kann als das menschliche Auge.
- Exclusive distribution rights for Curodont™ Repair Fluoride Plus to larger DSOs in the U.S.
- Potential for increased revenue through expansion into a growing market segment
- Complementary product to existing AI-enabled X-ray analysis tool Dentrix® Detect AI
- Strengthens Henry Schein's position as a leader in dental technology innovation
- None.
Insights
Henry Schein's exclusive distribution agreement with vVARDIS for Curodont™ Repair Fluoride Plus to larger DSOs in the U.S. is a strategic move that could positively impact the company's market position and financial performance. This partnership taps into the growing DSO segment, which is a key driver of market growth. The integration with Henry Schein One's Dentrix® Detect AI creates a synergistic offering that could enhance adoption rates and boost revenue streams.
While specific financial terms weren't disclosed, this agreement has the potential to increase Henry Schein's market share in the dental products sector. The company's position as the current market leader in selling Curodont™ to general practitioners and DSOs suggests a strong foundation for expansion. Investors should monitor future earnings reports for indications of revenue growth attributed to this partnership, as it could become a significant contributor to Henry Schein's dental segment performance.
The introduction of Curodont™ Repair Fluoride Plus represents a significant advancement in preventive dentistry. With
The synergy between Curodont™ and Dentrix® Detect AI is particularly noteworthy. The AI-enabled X-ray analysis tool's superior detection capabilities for incipient carious lesions, combined with Curodont's treatment approach, could revolutionize early caries management. This integrated solution has the potential to set a new standard in preventive dental care, possibly leading to reduced healthcare costs associated with advanced dental procedures and improved overall oral health on a population level.
Henry Schein's exclusive distribution agreement for Curodont™ to larger DSOs positions the company to capitalize on the rapidly growing DSO market segment. This move aligns with the industry trend towards consolidation and the increasing influence of DSOs in the dental care landscape. By securing exclusive rights in this segment, Henry Schein is strategically positioning itself as a key player in the evolving dental market structure.
The partnership also demonstrates Henry Schein's commitment to bringing innovative products to market, which could enhance its reputation among dental professionals. The potential for Curodont™ to become the new standard of care for early caries treatment could drive significant market demand. Investors should watch for adoption rates among DSOs and any shifts in market share within the dental products sector as indicators of the agreement's success and its impact on Henry Schein's competitive position.
Developed by vVARDIS, Curodont™ Repair Fluoride Plus is a proprietary solution that addresses early-stage tooth decay by aiding in the preventive treatment of cavity progression, with an innovative simple, quick, and drill-free application. It is widely recognized that poor oral health can impact overall health, and untreated decay can become life-threatening. Nearly
“We believe that Curodont advances clinical care by treating early decay before it worsens,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners. “With this treatment, the dental team can treat early-stage caries non-invasively and on the same day instead of sending patients home untreated. Henry Schein is pleased to bring products to market that improve clinical outcomes, including Curodont™ Repair Fluoride Plus, while helping practices operate more efficiently and effectively by advancing oral health and overall health for the ultimate benefit of the patient.”
The partnership between Henry Schein and vVARDIS builds on other innovations that support early treatment of oral disease. In late 2022, Henry Schein One introduced Dentrix® Detect AI, powered and manufactured by VideaHealth. Dentrix® Detect AI is an AI-enabled X-ray analysis tool that provides real-time clinical decision support and can detect incipient carious lesions more accurately than the naked eye, expanding the patient population that could benefit from the use of Curodont™ Repair Fluoride Plus. Dental professionals who use Dentrix® Detect AI and Curodont™ Repair Fluoride Plus in concert may help to more effectively treat early carious lesions before greater disease progression occurs.
Henry Schein currently is the market leader in selling Curodont™ Repair Fluoride Plus, with its novel approach, to general practitioners and DSOs. With this agreement, Henry Schein will have the exclusive rights to distribute Curodont™ Repair Fluoride Plus to larger DSOs, a market segment driving significant growth. The Company will continue to distribute Curodont products to other segments of the market and in other markets outside of
“We are excited to strengthen our partnership with Henry Schein, a recognized leader in driving technological innovation in dentistry,” said Drs. Haley and Goly Abivardi, DMDs, visionary Founders and Co-CEOs of vVARDIS. “Henry Schein’s global reach makes for an ideal partner as we share a common goal: advancing oral health by providing access to innovative, non-invasive solutions. Through this partnership, almost every patient can now benefit from Curodont. As both dentists and entrepreneurs, we are thrilled to finally have and offer a novel approach to treating early decay. Dental professionals have been waiting for decades for a drill-free treatment that addresses the sub-clinical signs of caries immediately, without sending patients home untreated and compromising their overall health. With its seamless integration into existing workflows, we believe that Curodont has the potential to rapidly become the new standard of care for the treatment of early caries, broadening the scope of services offered and empowering dentists and hygienists to lead the way in the management of early caries, ultimately enhancing patient care.”
About Henry Schein, Inc.
Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 25,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.
Henry Schein operates through a centralized and automated distribution network, with a selection of more than 300,000 branded products and Henry Schein corporate brand products in our distribution centers.
A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in
For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, Instagram.com/HenrySchein, and @HenrySchein on X.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240916637611/en/
Ann Marie Gothard
Vice President, Global Corporate Media Relations
annmarie.gothard@henryschein.com
(631) 390-8169
Source: Henry Schein, Inc.
FAQ
What is the new product Henry Schein (HSIC) will distribute to dental service organizations?
How does Curodont™ Repair Fluoride Plus benefit dental practices and patients?
What is the significance of Henry Schein's (HSIC) partnership with vVARDIS?
How does Curodont™ Repair Fluoride Plus relate to Henry Schein's (HSIC) Dentrix® Detect AI?
